Cite
Application of Multi-Criteria Decision Analysis (MCDA) to Prioritize Real-World Evidence Studies for Health Technology Management: Outcomes and Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration.
MLA
Takhar, Pam, et al. “Application of Multi-Criteria Decision Analysis (MCDA) to Prioritize Real-World Evidence Studies for Health Technology Management: Outcomes and Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration.” Current Oncology, vol. 31, no. 4, Apr. 2024, pp. 1876–98. EBSCOhost, https://doi.org/10.3390/curroncol31040141.
APA
Takhar, P., Geirnaert, M., Gavura, S., Beca, J., Mercer, R. E., Denburg, A., Muñoz, C., Tadrous, M., Parmar, A., Dionne, F., Boehm, D., Chambers, C., Craig, E., Trudeau, M., Cheung, M. C., Houlihan, J., McDonald, V., Pechlivanoglou, P., Taylor, M., & Wasylenko, E. (2024). Application of Multi-Criteria Decision Analysis (MCDA) to Prioritize Real-World Evidence Studies for Health Technology Management: Outcomes and Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration. Current Oncology, 31(4), 1876–1898. https://doi.org/10.3390/curroncol31040141
Chicago
Takhar, Pam, Marc Geirnaert, Scott Gavura, Jaclyn Beca, Rebecca E. Mercer, Avram Denburg, Caroline Muñoz, et al. 2024. “Application of Multi-Criteria Decision Analysis (MCDA) to Prioritize Real-World Evidence Studies for Health Technology Management: Outcomes and Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration.” Current Oncology 31 (4): 1876–98. doi:10.3390/curroncol31040141.